Agios Pharma (AGIO) Misses Q2 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Trump threatens to bomb Oman over Iran stance
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Agios Pharma (AGIO) PT Raised to $55 at RBC Capital
August 2, 2024 6:21 AM EDTRBC Capital analyst Kennen MacKay raised the price target on Agios Pharma (NASDAQ: AGIO) to $55.00 (from $53.00) while maintaining a Outperform rating.
The analyst comments "AGIO reported its 2Q24 update concurrent with the ACTIVATE-KidsT (pediatric PKD) topline results which missed the prespecified... More
